Tag: Reverse transcriptase inhibitor

In 1987, azidothymidine (AZT) became the first FDA-approved medication for treating HIV/AIDS, marking a pivotal moment in the fight against the virus. Understanding **how does AZT affect viral replication?** is key to appreciating this drug's historical and pharmacological significance in HIV management.

First approved in 1987, the drug azidothymidine (AZT), now known as zidovudine, was the first medication to be made available for the treatment of HIV/AIDS, offering a glimmer of hope during a critical period of the epidemic. Its effectiveness hinges on its ability to inhibit a specific viral enzyme: HIV reverse transcriptase.

With lifelong antiretroviral therapy, the life expectancy for people living with HIV now approaches that of the general population. A key question in ongoing research is, **what type of drug is Islatravir?** It is a first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTTI).